National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
niddk.nih.govTotal trials
534
Active
62
Phase 3
72
Total enrollment
231,610
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 33 of 33 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Epclusa | — | — | — | — | — | 1 | |
| Metreleptin | — | — | — | — | 5 | ||
| 18F-FCH | — | — | — | — | — | 1 | |
| Mirabegron | — | — | — | — | 2 | ||
| Thyrogen | — | — | — | — | 2 | ||
| Dexamethasone | — | — | — | — | — | 3 | |
| Antithymocyte Globulin | — | — | — | — | — | 2 | |
| Teplizumab | — | — | — | — | — | 2 | |
| rituximab | — | — | — | — | — | 2 | |
| 68Ga-DOTATATE | — | — | — | — | — | 2 | |
| 18F-DOPA | — | — | — | — | — | 2 | |
| Rituximab-pvvr | — | — | — | — | — | 1 | |
| Abatacept | — | — | — | — | — | 1 | |
| Sterile Sodium Chloride | — | — | — | — | — | 1 | |
| High-dose methylprednisolone | — | — | — | — | — | 1 | |
| Equine anti-thymocyte globulin | — | — | — | — | — | 1 | |
| Prednisolone | — | — | — | — | — | 1 | |
| Diphenhydramine | — | — | — | — | — | 1 | |
| Methylprednisolone | — | — | — | — | — | 1 | |
| 68-Gallium-DOTATATE-PET/CT | — | — | — | — | — | 1 | |
| Pegvisomant | — | — | — | — | — | 1 | |
| VIR-2218 and peginterferon alfa-2a | — | — | — | — | — | 1 | |
| Alpha-lipoic acid | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | — | 1 | |
| Rezpegaldesleukin | — | — | — | — | — | 1 | |
| 177Lu-DOTA-EB-TATE | — | — | — | — | — | 1 | |
| Rosuvastatin | — | — | — | — | — | 1 | |
| Abrocitinib 200 MG Oral | — | — | — | — | — | 1 | |
| Ritlecitinib | — | — | — | — | — | 1 | |
| Desmopressin | — | — | — | — | — | 1 | |
| Oral Cyclosporine | — | — | — | — | — | 1 | |
| [18F]-DOPA | — | — | — | — | — | 1 | |
| 68-Gallium Dotatate | — | — | — | — | — | 1 |
Next readouts
- 2019-10-23
- 2026-06-30
- 2026-08
- 2026-08-31
- 2026-09-30
- 2027-03-31
- 2027-07-31
- 2027-07-31
- 2027-12-31
- 2028-01-30
Top conditions
- Obesity88
- Diabetes26
- Healthy Volunteers19
- Diabetes Mellitus18
- Diabetes Mellitus, Type 218
- Overweight13
- Type 2 Diabetes13
- Healthy12
Frequently asked questions about National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- How many clinical trials does National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) have on ClinicalTrials.gov?
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is listed as the lead sponsor on 534 clinical trials in ClinicalTrials.gov, 62 of which are currently active (recruiting, enrolling, or ongoing).
- How many of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials are in Phase 3?
- 72 of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials are in Phase 3, spread across 33 active drug programs.
- What therapeutic areas does National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) focus on?
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s most-studied conditions on ClinicalTrials.gov are Obesity, Diabetes, Healthy Volunteers, Diabetes Mellitus, Diabetes Mellitus, Type 2.
- When are National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s next clinical trial readouts?
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has 10 upcoming primary-completion readouts tracked here; the soonest is “Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance”, expected around 2019-10-23.